Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

49.56
+0.23000.47%
Volume:45.17K
Turnover:2.24M
Market Cap:2.38B
PE:-16.24
High:50.19
Open:49.90
Low:49.00
Close:49.33
52wk High:50.34
52wk Low:14.11
Shares:47.98M
Float Shares:30.39M
Volume Ratio:0.58
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:5.62
PE(LYR):-17.31

Loading ...

Rapport Therapeutics Q4 Loss Widens

MT Newswires Live
·
Mar 10

Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate

Benzinga Earnings
·
Mar 10

Earnings Flash (RAPP) Rapport Therapeutics Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.70 Loss

MT Newswires Live
·
Mar 10

Press Release: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 10

Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Mar 10

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Reuters
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

Reuters
·
Mar 09

BUZZ-Rapport Therapeutics rises on granting China rights for epilepsy drug

Reuters
·
Mar 09

Rapport Therapeutics Shares up 4.3% Premarket as It Grants China Rights for Epilepsy Drug

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics Inc - to Receive $20 Mln Upfront, up to $308 Mln in Milestones, and Tiered Royalties

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics Inc - Tenacia Obtains Exclusive Rights to Develop and Commercialize Rap-219 in Greater China

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics Inc - Phase 3 Program for Rap-219 Expected to Start in Q2 2026 With Trial Sites in China

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

GlobeNewswire
·
Mar 09

Rapport Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview

Reuters
·
Mar 06